REPLIGEN CORP Cost of Revenue
REPLIGEN CORP (RGEN) reported Cost of Revenue of $94.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-29
- REPLIGEN CORP cost of goods and services sold for the quarter ending 2026-06-30 was $94.09M, a 5.28% increase year-over-year.
- REPLIGEN CORP cost of goods and services sold for the quarter ending 2026-03-31 was $85.97M, a 10.50% increase year-over-year.
- REPLIGEN CORP cost of goods and services sold for the quarter ending 2025-12-31 was $94.08M, a 26.90% decline year-over-year.
- REPLIGEN CORP cost of goods and services sold for the quarter ending 2025-09-30 was $88.29M, a 14.09% increase year-over-year.
- REPLIGEN CORP cost of goods and services sold for fiscal 2025 was $352.01M, a 2.16% decline from fiscal 2024.
- REPLIGEN CORP cost of goods and services sold for fiscal 2024 was $359.79M, a 1.66% increase from fiscal 2023.
- REPLIGEN CORP cost of goods and services sold for fiscal 2023 was $353.92M, a 2.34% increase from fiscal 2022.
- REPLIGEN CORP cost of goods and services sold for fiscal 2022 was $345.83M, a 23.83% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $94.09M 10-Q · filed 2026-07-29 | $180.06M 10-Q · filed 2026-07-29 | $274.14M derived: sum of 3 quarters · filed 2026-07-29 | $362.43M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2026-03-31 | $85.97M 10-Q · filed 2026-05-06 | $180.05M derived: sum of 2 quarters · filed 2026-05-06 | $268.34M derived: sum of 3 quarters · filed 2026-05-06 | $357.71M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2025-12-31 | $94.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $182.37M derived: sum of 2 quarters · filed 2026-02-26 | $271.74M derived: sum of 3 quarters · filed 2026-07-29 | $352.01M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $88.29M 10-Q · filed 2025-11-04 | $177.66M derived: sum of 2 quarters · filed 2026-07-29 | $257.93M 10-Q · filed 2025-11-04 | $384.17M derived: sum of 4 quarters · filed 2026-07-29 | ||
| 2025-06-30 | $89.37M 10-Q · filed 2026-07-29 | $91.22M 10-Q · filed 2025-08-07 | $167.17M 10-Q · filed 2026-07-29 | $169.64M 10-Q · filed 2025-08-07 | $295.88M derived: sum of 3 quarters · filed 2026-07-29 | $373.26M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $77.80M 10-Q · filed 2026-05-06 | $78.42M 10-Q · filed 2025-04-29 | $206.51M derived: sum of 2 quarters · filed 2026-05-06 | $283.89M derived: sum of 3 quarters · filed 2026-05-06 | $361.20M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $128.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $206.09M derived: sum of 2 quarters · filed 2026-02-26 | $283.40M derived: sum of 3 quarters · filed 2026-02-26 | $359.79M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $77.38M 10-Q · filed 2025-11-04 | $154.70M derived: sum of 2 quarters · filed 2025-11-04 | $231.09M 10-Q · filed 2025-11-04 | $319.22M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $77.31M 10-Q · filed 2025-08-07 | $153.71M 10-Q · filed 2025-08-07 | $241.84M derived: sum of 3 quarters · filed 2026-02-26 | $346.48M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $76.39M 10-Q · filed 2025-04-29 | $164.53M derived: sum of 2 quarters · filed 2026-02-26 | $269.16M derived: sum of 3 quarters · filed 2026-02-26 | $348.47M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $88.14M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | $192.77M derived: sum of 2 quarters · filed 2026-02-26 | $272.08M derived: sum of 3 quarters · filed 2026-02-26 | $353.92M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $104.63M 10-Q/A · filed 2024-11-18 | $183.94M derived: sum of 2 quarters · filed 2024-11-18 | $265.79M 10-Q/A · filed 2024-11-18 | $356.49M derived: sum of 4 quarters · filed 2025-03-14 | ||
| 2023-06-30 | $79.31M 10-Q/A · filed 2024-11-18 | $161.15M 10-Q/A · filed 2024-11-18 | $251.85M derived: sum of 3 quarters · filed 2025-03-14 | $338.37M derived: sum of 4 quarters · filed 2025-03-14 | ||
| 2023-03-31 | $81.84M 10-Q/A · filed 2024-11-18 | $172.54M derived: sum of 2 quarters · filed 2025-03-14 | $259.06M derived: sum of 3 quarters · filed 2025-03-14 | $345.32M derived: sum of 4 quarters · filed 2025-03-14 | ||
| 2022-12-31 | $90.70M derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | $177.21M derived: sum of 2 quarters · filed 2025-03-14 | $263.47M derived: sum of 3 quarters · filed 2025-03-14 | $345.83M 10-K · filed 2025-03-14 | ||
| 2022-09-30 | $86.51M 10-Q/A · filed 2024-11-18 | $172.77M derived: sum of 2 quarters · filed 2024-11-18 | $255.13M 10-Q/A · filed 2024-11-18 | $337.18M derived: sum of 4 quarters · filed 2024-11-18 | ||
| 2022-06-30 | $86.26M 10-Q/A · filed 2024-11-18 | $168.62M 10-Q/A · filed 2024-11-18 | $250.66M derived: sum of 3 quarters · filed 2024-11-18 | $326.16M derived: sum of 4 quarters · filed 2024-11-18 | ||
| 2022-03-31 | $82.36M 10-Q/A · filed 2024-11-18 | $164.40M derived: sum of 2 quarters · filed 2024-11-18 | $239.90M derived: sum of 3 quarters · filed 2024-11-18 | $301.89M derived: sum of 4 quarters · filed 2024-11-18 | ||
| 2021-12-31 | $82.05M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $157.54M derived: sum of 2 quarters · filed 2024-11-18 | $219.53M derived: sum of 3 quarters · filed 2024-11-18 | $279.28M 10-K/A · filed 2024-11-18 | ||
| 2021-09-30 | $75.50M 10-Q · filed 2022-11-01 | $137.49M derived: sum of 2 quarters · filed 2022-11-01 | $197.23M 10-Q · filed 2022-11-01 | $245.40M derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-06-30 | $61.99M 10-Q · filed 2022-08-02 | $121.74M 10-Q · filed 2022-08-02 | $169.90M derived: sum of 3 quarters · filed 2023-02-22 | $209.53M derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-03-31 | $59.75M 10-Q · filed 2022-04-27 | $107.91M derived: sum of 2 quarters · filed 2023-02-22 | $147.54M derived: sum of 3 quarters · filed 2023-02-22 | $184.40M derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2020-12-31 | $48.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $87.79M derived: sum of 2 quarters · filed 2023-02-22 | $124.65M derived: sum of 3 quarters · filed 2023-02-22 | $156.63M 10-K · filed 2023-02-22 | ||
| 2020-09-30 | $39.63M 10-Q · filed 2021-10-28 | $76.49M derived: sum of 2 quarters · filed 2021-10-28 | $108.47M 10-Q · filed 2021-10-28 | $138.59M derived: sum of 4 quarters · filed 2022-02-17 | ||
| 2020-06-30 | $36.86M 10-Q · filed 2021-07-27 | $68.84M 10-Q · filed 2021-07-27 | $98.97M derived: sum of 3 quarters · filed 2022-02-17 | $130.39M derived: sum of 4 quarters · filed 2022-02-17 | ||
| 2020-03-31 | $31.98M 10-Q · filed 2021-05-04 | $62.10M derived: sum of 2 quarters · filed 2022-02-17 | $93.53M derived: sum of 3 quarters · filed 2022-02-17 | $124.24M derived: sum of 4 quarters · filed 2022-02-17 | ||
| 2019-12-31 | $30.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $61.55M derived: sum of 2 quarters · filed 2022-02-17 | $92.25M derived: sum of 3 quarters · filed 2022-02-17 | $119.10M 10-K · filed 2022-02-17 | ||
| 2019-09-30 | $31.43M 10-Q · filed 2020-11-05 | $62.13M derived: sum of 2 quarters · filed 2020-11-05 | $88.98M 10-Q · filed 2020-11-05 | $112.57M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2019-06-30 | $30.71M 10-Q · filed 2020-07-30 | $57.55M 10-Q · filed 2020-07-30 | $81.14M derived: sum of 3 quarters · filed 2021-02-24 | $103.33M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2019-03-31 | $26.84M 10-Q · filed 2020-05-06 | $50.44M derived: sum of 2 quarters · filed 2021-02-24 | $72.62M derived: sum of 3 quarters · filed 2021-02-24 | $93.71M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2018-12-31 | $23.59M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $45.77M derived: sum of 2 quarters · filed 2021-02-24 | $66.86M derived: sum of 3 quarters · filed 2021-02-24 | $86.53M 10-K · filed 2021-02-24 | ||
| 2018-09-30 | $22.18M 10-Q · filed 2019-10-31 | $43.27M derived: sum of 2 quarters · filed 2019-10-31 | $62.94M 10-Q · filed 2019-10-31 | $82.08M derived: sum of 4 quarters · filed 2020-02-26 | ||
| 2018-06-30 | $21.09M 10-Q · filed 2019-08-01 | $40.76M 10-Q · filed 2019-08-01 | $59.89M derived: sum of 3 quarters · filed 2020-02-26 | $79.88M derived: sum of 4 quarters · filed 2020-02-26 | ||
| 2018-03-31 | $19.67M 10-Q · filed 2019-05-09 | $38.80M derived: sum of 2 quarters · filed 2020-02-26 | $58.79M derived: sum of 3 quarters · filed 2020-02-26 | $72.73M derived: sum of 4 quarters · filed 2020-02-26 | ||
| 2017-12-31 | $19.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $39.12M derived: sum of 2 quarters · filed 2020-02-26 | $53.06M derived: sum of 3 quarters · filed 2020-02-26 | $67.05M 10-K · filed 2020-02-26 | ||
| 2017-09-30 | $19.99M 10-Q · filed 2018-11-01 | $33.92M derived: sum of 2 quarters · filed 2018-11-01 | $47.91M 10-Q · filed 2018-11-01 | |||
| 2017-06-30 | $13.94M 10-Q · filed 2018-08-02 | $27.93M 10-Q · filed 2018-08-02 | ||||
| 2016-12-31 | $47.12M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |